Jon Napitupulu

Tenaya Therapeutics outlined a 2026 cadence aimed at moving two cardiac gene therapies toward pivotal-readiness while extending its cash...

Pliant Therapeutics has initiated a Phase 1b indication expansion trial for PLN-101095, an oral dual inhibitor of αvβ8 and...

Evaxion has delivered a 2025 reset built on external validation and extended runway. The techbio vaccine developer reported full-year...

Aquestive Therapeutics will resubmit the U.S. NDA for Anaphylm, its sublingual epinephrine film for severe allergic reactions, in the...

ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy, its FDA- and EC-approved intranasal epinephrine, in...

Santhera has appointed Marc Clausse as Chief Commercial Officer, effective June 1, 2026, succeeding Geert Jan van Daal, who...

Enzon Pharmaceuticals has extended the deadline for its exchange offer to convert Series C non-convertible redeemable preferred stock into...

TG Therapeutics will showcase new BRIUMVI (ublituximab-xiiy) data at AAN 2026 in Chicago, including the first Phase 4 real-world...

Ataibeckley has cleared a key regulatory hurdle for its lead program in treatment-resistant depression, securing FDA alignment at end-of-Phase...

Atea Pharmaceuticals has completed enrollment of its North American phase 3 C-BEYOND trial evaluating the fixed-dose combination of bemnifosbuvir...